Compare · JANX vs JNJ
JANX vs JNJ
Side-by-side comparison of Janux Therapeutics Inc. (JANX) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JANX and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $610.38B, about 576.4x JANX ($1.06B).
- Over the past year, JANX is down 38.2% and JNJ is up 32.3% - JNJ leads by 70.5 points.
- JNJ has hit the wire 16 times in the past 4 weeks while JANX has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 20 for JANX).
- Company
- Janux Therapeutics Inc.
- Johnson & Johnson
- Price
- $16.51-4.62%
- $255.53+0.88%
- Market cap
- $1.06B
- $610.38B
- 1M return
- -2.10%
- -5.45%
- 1Y return
- -38.25%
- +32.25%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 16
- Recent ratings
- 20
- 25
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JANX
- Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
- Janux Therapeutics upgraded by Wolfe Research with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.
- SEC Form 10-Q filed by Janux Therapeutics Inc.
- Janux Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
- President and CEO Campbell David Alan gifted 123,840 shares, decreasing direct ownership by 32% to 264,742 units (SEC Form 4)
- President and CEO Campbell David Alan exercised 7,000 shares at a strike of $4.21, increasing direct ownership by 2% to 388,582 units (SEC Form 4)
- Janux Therapeutics Inc. filed SEC Form 8-K: Other Events
- Director Ra Capital Management, L.P. was granted 5,500 shares (SEC Form 4)
Latest JNJ
- SEC Form 8-K filed by Johnson & Johnson
- Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
- Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
- TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
- New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
- New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause